



human CAP-1

MLSHNTMMQRKQQATAIMKEVHGNDVDGMDLGGKVSI PRDIMIEELSHLSNRGARLFKM
60
RQRRSQDKYTTFENFQYQSRQINHSTIAMQNGKVDGSNLEGGSQQAPLTPPNTPDRSPPNP
120
DNIAPGYSSGPLKEIPPEKFTNTTAVPKYQSPWEQAISNDPELLEALYPKLKFKEEGKAELP
180
DYSFENRVATPFGGEFEKASRMVKFKVPDFELLLTDPREMSEVNPLSGRRSFENRTPKGWV
240
SENIPIVITTEPTDDTTVPESEDL

FIG. 1A

mouse CAP-1

MLSHSAMVQRKQQASAITKEIIGHGDVDGMDLGGKVSI PRDIMIEELSHLSNRGARLFKM
60
RQRRSQDKYTTFENFQYQESRAQINENNTIAMQNGRVDGSNLEGGSQQGPSTPPNTPDRSPPNP
120
ENIAPGYSSGPLKEIPPERFNTTAVPKYRSPWEQAIGSDPELLEALYPKLKFKEEGKAELR
180
DYSFENRVATPFGGEFEKASRMVKFKVPDFELLLTDPREMSEVNPLSGRRCFNRAPKGV
240
SENIPVVIITTEPTEDATVPESDL

FIG. 1B

#3

human CAP-2

MPLSGTPAPNKKRKSSKLIMELTGGQESSGLNLGKKISVPRDVMLEELSLTNRGSKMF
60
KLRQMRVEKFIYENHPDVFSDSMDFQKFLPPTVGGQLGTAGQQGESYSKSNGRGSSQAGG
120
SGSAGQYGSDDQHHLGSGAGGTGGPAGQAGRGAAGTAGVGETGSDQAGGECKHITV
180
FKTYTSPWERAMGVDPQQKMEIGIDLLAYGAKAELPKYKSFNRNTAMPYGGYEKASKRMTF
240
QMPKFDLGPLLSEPIVLVLYNQNLNSNRPSENRTPIPWLSSGEPVDVNVDIGIPLDGETEEL

FIG. 1C

mouse CAP-2

MPLSGTPAPNKKRKSSKLIMELTGGRESSGLNLGKKISVPRDVMLEELSLTNRGSKMF
60
KLRQMRVEKFIYENHPDVFSDSMDFQKFLPPTVGGQLETAGQQGESYKGSSGGQAGSSG
120
SAGQYGSDRHQQGSGFAGGSGGPGQAGGGAPTVGLGEPGSGDQAGDGKHKVTVFKT
180
YISPWDRAAMGVDPQQKVVELGIDLLAYGAKAELPKYKSFNRNTAMPYGGYEKASKRMTFQMP
240
KFDLGPLLSEPIVLVLYNQNLNSNRPSENRTPIPWLSSGEHVVDVGVIPILDGETEEL

FIG. 1D

FIG. 1E

human CAP-1

FIG. 2A

mouse CAP-1

10	20	30	40	50	60	70	80	90	100
ATTGGGCACATGGGATCGAGGGACCATGCGGTCCAGGTTCAAGGATAAAACCCATTGGGCCATAGTGCGTCATATTCCACCTCAGGCCCTCCCA									
TAACCCGTGACCTAGCTCCCTGGTACGGCAAGGTCAAAGTCTTATTTGGTACCGGTATCACGGCAGTATAAGGTGGANGTCACCGGAAGGAGGT									
110	120	130	140	150	160	170	180	190	200
CAATTGGGATTCACCCCTGGTGAAGGGCAGCGTGCAGCGAAGGGAAACAAAACATGCTATCACAATGCTATCAGTGGCCATGGTGAAGCAAAGGAAACAGCAAG									
GTTAACCTTAAGTGGGACACTTTGGCTGGGACTGTGCTCCCTGTTTTGATACGATAGTGTACCGTACCCACTTCGTTCTTGTGTC									
210	220	230	240	250	260	270	280	290	300
CATCAGCCATCACCAAGGAATCCATGGCAGTGTGTTACGGCATGGACCTGGGAAAGGGAAAAAGTTAGCATCCCAGACACATCATGATAGAAGAAATTGTC									
GTACTCGGTAGTCCTCTTCTTAGGTAACCTGTACTAACATGGCTACCTGGGATCCCTGGACCCGTTTTCACTCGTAGGGTCTGTAGTACTATCTTAAACAG									
310	320	330	340	350	360	370	380	390	400
CCATTTCACTAATCGTGGGCCAGGGCTGTTAAGATGCTCAAGAGATCTGACAAATACACCTTGAAATTCTCCAGTATGAACTCTAGGCACAAATT									
GGTAAGTCATTAGCACCCCCGGTCCGACAAATTCTACGCAGTTCTAGCTTATGCGAATCTTAAAGGTCAACTTATGATCTCGTGTAA									
410	420	430	440	450	460	470	480	490	500
AATCACAAATATGCCATGCCAAATGGGAGACTGTGATGGAAACCAACTGGAAAGGTGGCTCACGCCAGGGCCCTCACTCCGCCAACACCCCCGATCCAC									
TTAGTCCTTATGGGTACCGTCTTACCCCTCAACTACCTTCGTTGGACCTTCACCCAGTGTGTTCCGGGAGTTGCGGGGTGTGGGGCTAGCTG									
510	520	530	540	550	560	570	580	590	600
GAACCCCCAAATCCAGAGAAACATCGCACCCAGGATATCTGGACCACTGTGAGGAATTCCCTCGTGAAGGTTAACCGACGGCGCTCTTAAGTACT									
CTTCGGGGGTTTAGGTCTTGTAGCGTGGCTCTATAAGACCTGGTACTCTCTTAAAGGAGGACTTCAAATTGTGCTGCCGCAAGGATTCATGAT									
610	620	630	640	650	660	670	680	690	700
CCGGTCATGGGAGCAGGGATTGGCACGGATCGGAGGCTCTGGAGGCTTGTACCCAAATTCTCAAGCTGAAGGAAAGGACAACTGGGGAT									
GGCCAGAGGTACCCCTGTCGGTAAACCGTCGCTAGGCCCTCGAGGACCTCGAACATGGGTTTGAAAGTGGACTTCTTTCTGCTTGACGCCCTA									
710	720	730	740	750	760	770	780	790	800
TACAGGAGCTTAAACAGGTGGCACTCCATTGGAGGTTTGAAAAGCATCRAATTGGTCRAATTCACAGTCCAGATTTCGAACTACTGTGCTGA									
ATGTCCTCGAAATTGTCCTAACGGTGGAGTAAACCTCCAAACTTTCTCGTAGTTTACAGTTAAGTCAGGCTTAAACCTGATGACGCCACT									
810	820	830	840	850	860	870	880	890	900
CAGATCCCAAGCTTCTGCCCAATCCCTTTCGGCAGACGATCCCTAACAGGGCCCAAGGGCTGGCTATCTGAGAATATCCCCGTCGTGAT									
GTCAGGGTCAAGAACGGAAACGGTTAGGAGMAGCCGTCGCTACGAATGTGCTCCGGGTTTCCCACCCATAGACTCTTATAGGGCAGCACTA									
910	920	930	940	950	960	970	980		
CACAACTGACCCCTACAGAAAGACCCACTGTACCGGAATCAGATGACCTGTGAGAGGGAGCTGGGATGCCACAGGAAGTTC									
GTTGAGCTGGATGCTCTGGGAGACATGCCCTAGCTACTGGACACTCTCCCTACGGACACTCTCCCTACGGTGTCTCAAG									

FIG. 2B

human CAP-2

CGGTACAGC AGCTCAGTCC TCCAAAGCTG CTGGACCCCA GGGAGAGCTG ACCACTGCCG GAGCACCGG CTGAATCCAC CTCCACAATG CCGCTCTCAG
200
GAACCCCGGC CCTAATAAAG AAGAGGAAAT CCAGCAGCT GATCATGGAA CTCACCTGGAG CTGGACAGGA GAGCTCAGGC TTGACCTGG GCAAAAAACAT
300
CACTGTCCCA AGGGATGTCA TGTTCGAGGA ACTCTCGTG CTTACCAACC GGGGCTCCAA GATGTTCAA CTGGCCAGA TGAGGGTGGA GAAGTTTATT
400
TATGAGAACC ACCCTGATGT TTCTCTGAC AGCTCAATGG ATCACTTCCA GAAGTTCCTT CCAGCAGCT GGGCACAGCT GGGCACAGCT GGTCAAGGGAT
500
TCTCATACAG CAAGACGACG GCGAGAGGGC GCAGCCAGGC AGGGGGCAGT GGCTCTCCCG GACAGTATGG CTCTGATCAG CAGCACCCATC TGGGCTCTGG
600
GTCTGGAGCT GGGGGTACAG GTGGTCCCCC GGGCCAGCT GGCAGAGGAG GACCTGCTGG CACACAGGGG GTGGTGAGA CAGGATCAGG AGACCAAGCA
700
GGGGAGAAG GAAAACATAT CACTGTGTC AAGACCTATA TTTCCCCATG GGAGCGAGCC ATGGGGTTG ACCCCCAGCA AAAATGGAA CTTGGCATTT
800
ACCTGCTGGC CTATGGGCC AAAGCTGAAC TTCCCCAATA TAAGTCCTTC AACAGGACGG CAATGCCCTA TGTTGGATAT GAGAAGGCCT CCAGAACCCAT
900
GACCTTCCAG ATGCCCAAGT TTGACCTGGG GCGCTTGCTG AGTGAACCCC TGTTCCCTTA CAACCAAAAC CTCTCCAAACA GGCCTTCTTT CAATCGAAC
1000
CCTATTCCT CGCTGAGCTC TCGGGACCT GTAGACTACA ACCTGATAT TGCGATCCCC TTGGATGGAG AACACAGGA CCTCTGAGGT GTTCTCTCT
CTGATTTGCA TCATTTCCCC TCTCTGGCTC CAATTTGGAG A

FIG. 2C

mouse CAP-2

CCCCGGGAGA CCCGACCAACC AACTGAGCAG CTGGTCAGAT CCACCTCCAC CATGCCACCC TCAGGAACCC CGGGCCCTAA CAAGAGGAGG AAGTCAGCA
100
AACTGATTAT GGAGCTCACT GGAGGTGGCC GGGAGAGCTC AGGCCTGAAAC CTGGGCAAGA AGATCACTGT CCCAAGGGAT GTGATGTGG ACCAGCTGTC
200
CCTCTTACCC AACCGAGGCT CCAAGATGTT CAAAGCTACGG CACATGGGG TGGAGAAATT TATCTATGAG AATCACCCCG ATGTTTCTC TGACAGCTCA
300
ATGGATCACT TCCAGAAGTT TCTTCCCACA GTGGGAGGAC AGCTGGAGAC AGCTGGTCAG GCCTTCTCAT ATGCCAAGGG CAGCAGTGGA GGCCAGGCTG
400
CCACCACTGG CTCTGGTGG AAGTATGGCT CTGACCCCTCA TCAGCAGGGC TCTGGTTTG GAGCTGGGG TTCAGTGTT CCTGGGGCCC AGCTGGTG
500
AGGAGGAGCT CCTGGCACAG TAGGGCTTGG AGAGCCCCGA TCAGGTGACC AGGCAGGTGG AGATGAAA CAACTGACTG TGTTCAAGAC TTATATTTCC
600
CCATGGGATC GGGCCATGGG GGTTGATCCT CAGCAAAAGG TGGAACTTGG CATTGACCTA CTGGCATAAG CTCAGCTGGT CCTGGGGCCC AGCTGGTG
700
ACCCCTGGTC CTCTACAAAC AGAACCTCTC CAACACCCCT TCTTTCATC GAGCCCTAT TCCCTGGTG AGCTCTGGGG ACCATGTAGA CTACACCTG
800
GATTTGGTA TCCCCTTGGG TGGAGAGACA GAGGAGCTGT GAAGTGGCTC CTCCCTGTCAT GTCCATCATT TCCCTTCTCT GGTTCCAATT TGAGACTGGA
900
TGCTGGACAG GATGCCCCAA CTGTTAATCC ACTATTCTTG TGGCAATGGA CGGTAAACGG TGGGGTCCGT TGGCTTCCA CCCTCAAGT TCTGCTCCG
1000
AAGCATCCCT CCTCACCCAGC TCAGAGCTCC CATCTGGCTG TACCATATGG AATCTGCTCT TTTATGGAAT TTCT

FIG. 2D




FIG. 3

FIG. 4A




FIG. 4C




FIG. 4B




FIG. 4E




FIG. 5A




FIG. 5B



α-actinin CnA IgG heavy chain Cs-1 + α-actinin Cs-1 + CnA Cs-2 + α-actinin Cs-2 + CnA

FIG. 6A




FIG. 6B





FIG. 6C






FIG. 7




FIG. 8

Calsarcin-3





FIG. 9

FIG. 10




FIG. 11





FIG. 12



20. (Continued)
1000 2000 3000 4000 5000 6000 7000 8000 9000 10000

ClustalW Formatted Alignments

calsarcin-3	1	M P . . . S E Q K G P M A A G D L T E P V P T L D L G K K S V P Q D M M E E I S L R N N R	47
calsarcin-2	1	M P L S G T P A P R K R E S S K M E T G C Q E S S G L N L G K K S V P R D M L E E I S L I S N R	53
calsarcin-1	1	M L S H T N K O R K Q Q A I N K E Y H G . . N D V D G M D L G K K S P R D M L E E I S H L S N R	53
calsarcin-3	48	G S L F Q K R Q R R V Q K F T F L A S Q R A M L A G S A R R K V T Q A S S G T V A N A N G P E O P N Y	102
calsarcin-2	56	G S K M V K R Q M R V K F I M E N H P D V . F S D S S M D H F Q K F T P C V G G Q G Q Q F S . Y S	108
calsarcin-1	54	G A R L F K R Q R R S D K T F E N . . . F Q Y Q S R A Q I N H S I A M O N G K V D . . . G . . . 94	
calsarcin-3	103	P S E L I F P A S P G A S L Q G P E G A H P A A A P A G C V P S F S A T A P G Y A E P L K O N P P . . .	152
calsarcin-2	109	S N Q G G S Q A Q G Q S D Q O H H L G . . . S G S G A G G T O G P A Q Q A G K G G A A G	158
calsarcin-1	95	S N L E G G S Q Q . . A P L P P N T P D P E S P E N . . . P D N Y A P G Y S G P L K E P P . . . 136	
calsarcin-3	153 E K F N H I T A P K G Y E C P W Q E F O S Y R D Y Q S D G R S	183
calsarcin-2	159	T T Q V Q E T G S Q D Q A G G E G K H I I V E K T Y I S P W E R A X G V D P Q C K M E L Q I D E L A Y G A R A	213
calsarcin-1	137 E K F N T T A V P K Y Y S P W E A S N D P E L L E A L Y P K L F K P E G K A	177
calsarcin-3	184	H T P S P N D Y R N F N K T P A P F G G P L V Q G . . . T F P P R P . . . G T P F I F E P S Q E E L R L R	231
calsarcin-2	214	E L P . . . K Y S F N R T A P M G G N R M T F Q M P K F D L G P P L S E P L V A N Q N E S N R	265
calsarcin-1	178	E L P . . . D Y R S F N R V A T P F G G A E K A S P M V K F K Y P D F E L L E H T D P R F M S S V N P L S G R	229
calsarcin-3	232	P S F N R V A Q G W R N L P E S . . . E E L	231
calsarcin-2	266	P S F N R T P I P W S S G E P D Y N V D I G I P L D G . . E T E E L	299
calsarcin-1	230	R S F N R T P G W S S E N I F V I T T E P T D D T T V P F E S E D L	264

FIG. 13